Document is current
Any future updates will be listed below
-
Authors
Meijnikman, Abraham S. https://orcid.org/0000-0002-6015-4656
Davids, Mark https://orcid.org/0000-0003-3081-9124
Herrema, Hilde
Aydin, Omrum https://orcid.org/0000-0003-0296-5968
Tremaroli, Valentina
Rios-Morales, Melany https://orcid.org/0000-0002-3028-7562
Levels, Han
Bruin, Sjoerd
de Brauw, Maurits
Verheij, Joanne
Kemper, Marleen https://orcid.org/0000-0003-2275-1713
Holleboom, Adriaan G.
Tushuizen, Maarten E.
Schwartz, Thue W. https://orcid.org/0000-0002-0261-6904
Nielsen, Jens
Brandjes, Dees
Dirinck, Eveline
Weyler, Jonas
Verrijken, An
De Block, Christophe E. M.
Vonghia, Luisa
Francque, Sven https://orcid.org/0000-0002-7527-4714
Beuers, Ulrich https://orcid.org/0000-0001-5114-7799
Gerdes, Victor E. A.
Bäckhed, Fredrik
Groen, Albert K.
Nieuwdorp, Max https://orcid.org/0000-0002-1926-7659
- License Information
-
More Information
Article History
Received: 7 February 2022
Accepted: 17 August 2022
First Online: 10 October 2022
Competing interests
: M.N. is on the scientific board of Caelus Pharmaceuticals, Netherlands. F.B. is on the scientific board of Metabogen AB, Sweden. However, none of these are directly relevant for the current paper. S.F. has acted as advisor and/or lecturer for Roche, Gilead, Abbvie, Bayer, BMS, MSD, Janssen, Actelion, Astellas, Genfit, Inventiva, Intercept, Genentech, Galmed, Promethera, Coherus and NGM Bio. However, none of these are directly relevant for the current paper. A.G.H. has consulted for Novo Nordisk, Gilead, Amgen, Echosens and Julius Clinical. The remaining authors declare no competing interests.
